La Jolla Institute for Allergy & Immunology   Report issue

Academic/Hospital Phase 2
Founded: La Jolla CA United States (1988)

Organization Overview

First Clinical Trial
2010
NCT01085201
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

La Jolla Institute for Allergy & Immunology

Active Ingredients

Drugs in Phase 2 Trials (1)

regadenoson (lexiscan) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 2)

Anemia, Sickle Cell (Phase 2)

Hypersensitivity (Phase 1)

Milk Hypersensitivity (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1